Retinal dystrophy is a chronic and progressive disorder of visual function. This is the condition associated with deteriorating vision one or both eyes. Mostly retinal dystrophies are genetic and are passed down from parents. Basically, Retinal dystrophy is a genetically heterogeneous disorder which is one of the causes of blindness. Retinal dystrophies are degeneration of different cells types within the retina. Retinal dystrophy is an inherited eye disorder that damages functional cells in the retina that transmits light from the eye to the brain via the optic nerve. Retinal dystrophy patients usually show symptoms by age 20 with reduced color and central vision. Common presentation among these disorders includes color or night blindness, tunnel vision, and subsequent progression to complete blindness. Retinal cell types involved in the retinal dystrophies include the rods and cones
The increasing rate of Retinal disease expected to drive the growth of retinal dystrophy treatment market increasing awareness about fundus albipunctatus which is caused by a mutation in the gene encoding 11 Cis retinol expected to drive the market growth. Oral treatment with 9 Cis beta carotene led to retinal dystrophy and this potential therapy expected to grow the retinal dystrophy market. Retinal disease treatment option and diagnosis of the disease further expected to enhance the growth of retinal dystrophy treatment market. Increasing expenditure research and developments by the product manufacturing companies in the retinal dystrophy market expected to increase revenue generation in near future New and emerging technologies for the treatment of retinal dystrophy enhance the market growth. Latest gene therapy for the treatment of retinal dystrophy is anticipated to grow the retinal dystrophy market. These are some of the factors responsible for driving the growth of the global retinal dystrophy treatment market. However, factors like low insurance coverage and reimbursement issues might hamper the growth of the global retinal dystrophy treatment market.
The global Retinal dystrophy treatment market is segmented by Treatment type and Distribution channel:
Based on treatment type, the global Retinal dystrophy treatment market is segmented into:
Based on the end-user, the global Retinal dystrophy treatment market is segmented into:
The increasing prevalence of the retinal disease expected to contribute to retinal dystrophy treatment market. Based on treatment type, Retinal dystrophy treatment market is expected to be dominated by gene therapy treatment whereas by distribution channel Retinal dystrophy treatment market is expected to be dominated by the hospital and retail pharmacies. The manufactures in Retinal dystrophy treatment market are focusing on the development of a new formulation for the Retinal dystrophy treatment
The global Retinal dystrophy treatment market is expected to be dominated by North America due to higher treatment seeking rate and higher penetration of Retinal dystrophy treatment options. Europe is expected to be the second most lucrative Retinal dystrophy treatment market due to a comparatively higher prevalence of Retinal dystrophy coupled with higher treatment seeking rate. Asia-Pacific is expected to be the fastest growing Retinal dystrophy treatment market due to rapidly increasing awareness about the disease and increasing product penetration in the region. Presence of one of the fastest growing economies such as India and China further expected to drive the growth of Retinal dystrophy treatment market in the APAC region. Latin America Retinal dystrophy treatment market is expected to witness steady growth due to increased diagnosis of the condition in the region. The Middle East and Africa is least lucrative Retinal dystrophy treatment market due to low treatment seeking rate, low product penetration, and low diagnosis rate. Overall, global Retinal dystrophy treatment market expected to witness significant growth due to increasing penetration of products and diagnosis.
Examples of some of the key players in the global Retinal dystrophy market are Spark Therapeutics, Novartis AG, GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Applied Genetic Technologies Corporation, Oxford BioMedica, Epeius Biotechnologies, Abeona ,sTransgene SA, and others.
The report covers exhaustive analysis on:
The regional analysis includes:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.